CNTB Connect Biopharma
- 1.7700
- +0.1000+5.99%
- 1.7667
- -0.0033-0.19%
Connect Biopharma News
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results From the Global Phase 2b Trial of Rademikibart in Patients With Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical
Sector Update: Health Care Stocks Retreating Late Afternoon
Health care stocks eased in late Wednesday afternoon trading, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each decreasing 0.1%. The iShares Biotechnology ETF (IBB
Sector Update: Health Care
Health care stocks ease in late Wednesday afternoon trading with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both decreasing 0.1%. The iShares Biotechnology ETF (IBB)
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer
Connect Biopharma (CNTB) is terminating its in-license agreement for CBP-174, an antiallergic, with Pfizer (PFE), effective May, to optimize resources and extend its cash runway The company said Tuesd
Connect Biopharma Is Maintained at Buy by HC Wainwright & Co.
Connect Biopharma Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The rating of Conrad Biopharmaceuticals (CNTB.US) was maintained, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $8.00.
HC Wainwright & Co. : The rating of Conrad Biopharmaceuticals (CNTB.US) was maintained, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $8.00.
HC Wainwright & Co. Maintains Buy on Connect Biopharma Hldgs, Raises Price Target to $8
HC Wainwright & Co. analyst Emily Bodnar maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and raises the price target from $7 to $8.
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB) and Clene (CLNN) with bullish sentiments.
Connect Biopharma Triumphs With Rademikibart Trials
Connect Biopharma GAAP EPS of -$2.15 Misses by $1.33
Connect Biopharma Hldgs FY EPS $(1.08) Up From $(2.15) YoY
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(1.08) per share. This is a 49.77 percent increase over losses of $(2.15) per share from the same period last year.
Press Release: Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update -- Reported two positive readouts for rademikibart, the Company's lead asset, from the Global Phase 2b
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Reported two positive readouts for rademikibart, the Company's lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe
Buy Rating Reaffirmed for Connect Biopharma Holdings Amid Promising Clinical Trials and Strategic Partnerships
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
MMAT, CNTB and HGAS Among Mid-day Movers
ADRs End Higher; Connect Biopharma Holdings Climbs 21%
This article was automatically generated by Dow Jones Newswires using technology from Automated Insights. International stocks trading in New York closed higher on Wednesday, as the S&P/BNY Mellon in
Connect Biopharma Initiated at Buy by HC Wainwright & Co.
Connect Biopharma Initiated at Buy by HC Wainwright & Co.
Connect Biopharma Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/04/2024 438.46% HC Wainwright & Co. → $7 Initiates Coverage On → Buy 09/13/2023 284.62% Cantor Fitzgera
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
Analysis
Price Target
No Data
